DDInter667 DDInter899
Erlotinib is an inhibitor of the epidermal growth factor receptor (EGFR) tyrosine kinase that is used in the treatment of non-small cell lung cancer, pancreatic cancer and several other types of cancer. It is typically marketed under the trade name Tarceva. Erlotinib binds to the epidermal growth factor receptor (EGFR) tyrosine kinase in a reversible fashion at the adenosine triphosphate (ATP) binding site of the receptor. Recent studies demonstrate that erlotinib is also a potent inhibitor of JAK2V617F, which is a mutant form of tyrosine kinase JAK2 found in most patients with polycythemia vera (PV) and a substantial proportion of patients with idiopathic myelofibrosis or essential thrombocythemia. This finding introduces the potential use of erlotinib in the treatment of JAK2V617F-positive PV and other myeloprolifer
Ibrutinib is a small molecule that acts as an irreversible potent inhibitor of Burton's tyrosine kinase. It is designated as a targeted covalent drug and presented as a promising activity in B-cell malignancies in clinical trials. Ibrutinib was developed by Pharmacyclics Inc and was first approved by the FDA in November 2013 for the treatment of mantle cell lymphoma (MCL) under accelerated approval; however, in April 2023, the drug manufacturer withdrew the accelerated approvals for ibrutinib in the US. Ibrutinib was approved by the EMA in October 2014 and by Health Canada in November 2014. It is currently approved for the treatment of various conditions, such as chronic lymphocytic leukemia (CLL), Waldenström's Macroglobulinemia, and chronic graft versus host disease (cGVHD) in August 2017. Notably, ibrutinib became the first FDA-approved cGVHD treatment for children in August 2017.
Erlotinib {u} (Compound) resembles {v} (Compound) Vandetanib
Erlotinib {u} (Compound) resembles {v} (Compound) Gefitinib
Erlotinib {u} (Compound) treats {v} (Disease) kidney cancer
Erlotinib {u} (Compound) binds {v} (Gene) CYP1A2
Erlotinib {u} (Compound) upregulates {v} (Gene) IL1B
Erlotinib {u} (Compound) downregulates {v} (Gene) COX8A
Erlotinib {u} (Compound) causes {v} (Side Effect) Drug interaction
Erlotinib {u} may cause a minor interaction that can limit clinical effects when taken with {v} Modafinil
Erlotinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Cobicistat
Erlotinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Cimetidine
Erlotinib (Compound) resembles Vandetanib (Compound)
Erlotinib (Compound) resembles Gefitinib (Compound)
Erlotinib (Compound) treats kidney cancer (Disease)
Erlotinib (Compound) binds CYP1A2 (Gene)
Erlotinib (Compound) upregulates IL1B (Gene)
Erlotinib (Compound) downregulates COX8A (Gene)
Erlotinib (Compound) causes Drug interaction (Side Effect)
Erlotinib may cause a minor interaction that can limit clinical effects when taken with Modafinil
Erlotinib may cause a moderate interaction that could exacerbate diseases when taken with Cobicistat
Erlotinib may cause a moderate interaction that could exacerbate diseases when taken with Cimetidine